| Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial P Richmond, L Hatchuel, M Dong, B Ma, B Hu, I Smolenov, P Li, P Liang, ... The lancet 397 (10275), 682-694, 2021 | 272 | 2021 |
| Persistence of the immune responses and cross-neutralizing activity with variants of concern following 2 doses of adjuvanted SCB-2019 coronavirus disease 2019 vaccine PC Richmond, L Hatchuel, F Pacciarini, B Hu, I Smolenov, P Li, P Liang, ... The Journal of Infectious Diseases 224 (10), 1699-1706, 2021 | 20 | 2021 |
| A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy … P Richmond, L Hatchuel, M Dong, B Ma, B Hu, I Smolenov, P Li, P Liang, ... medRxiv, 2020.12. 03.20243709, 2020 | 7 | 2020 |
| Late Breaking Abstract—Multiple ascending dose study of the inhaled IL-4Ra antagonist I Bruns, M Fitzgerald, G Mensing, M Tsung, K Pardali, P Gardiner, ... AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a …, 2019 | 7 | 2019 |
| Late Breaking Abstract-Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising … I Bruns, M Fitzgerald, G Mensing, M Tsung, K Pardali, P Gardiner, ... European Respiratory Journal 54 (suppl 63), 2019 | 3 | 2019 |
| Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the … IB Bruns, MF Fitzgerald, G Mensing, M Tsung, K Pardali, P Gardiner, ... | | |
